Immuno-Oncology

Brianna Hoffner reminds oncology nurses to collaborate with colleagues in other departments when treating patients with immune-related adverse events.

Karen Lee discusses the managment of immune-related adverse events in patients who are receiving immunotherapy treatments.

Aside from the approved nivolumab, other immunotherapy combinations are being considered for Hodgkin lymphoma.

Laura Wood explains the education opportunities available to nurses in the field of immunotherapy.

Karen Lee, NP, explains the importance of keeping patients with cancer hopeful but realistic when starting immunotherapies.

Omid Hamid, MD, compares the responses of patients with melanoma on single-agent immunotherapy treatment to those on combination therapy treatments.

Brianna Hoffner, MSN, NP, RN, discusses complex immune-related adverse events and how nurses can go about treating patients.

For multiple myeloa and immunotherapy, combination treatment may be the best pathway to durable responses.

Dr. Jonathan Schoenfeld discusses the need for collaboration among teams when a patient is receiving a combination of immunotherapy and radiation treatment.

Dr. Sundar Jagannath discusses the benefits in progression-free survival and quality of life from newly-approved therapies for patients with multiple myeloma.

Immunotherapy expert, Dr. Jeffrey Weber, talks about the importance of early intervention for immune-related adverse events.

Dr. Jeffrey Weber describes the organ-specific side effects that can occur in a patient on checkpoint inhibitors.

Jonathan Schoenfeld discusses the patient profile that would benefit best from a combination of radiation and immunotherapy.

Immunotherapy agent atezolizumab approved by FDA for treatment of NSCLC.

Dr. Omid Hamid discusses some toxicities that come from combination immunotherapies

The treatment of TNBC is rapidly evolving, with immotherapies, AR-targeted agents and targeted therapies.

Yvonne Saenger, MD, from Columbia University, gives a rundown of the immunotherapy options for treating melanoma.

Between 2014 and 2016, the number of cancer survivors living in the United States rose by one million. This is just one of the many benefits the Cancer Progress Reports lists from cancer research.

Immunotherapy is changing the cancer treatment game as therapies continue to be approved for more and more tumor types. This creates more responsibilities for oncology nurses.

An oncology nurse's overview of immunotherapy.

Cancer immunotherapies continue to show promising clinical outcomes, notably long-lasting remission, for an increasing number of malignancies.

Some immune-related adverse events (irAEs) can be life threatening. Researchers in Spain recently published a review of the most common endocrine irAEs and their management strategies.

The immunotherapy pembrolizumab (Keytruda) has been granted an accelerated approval from the FDA for the treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) whose disease progresses after platinum-based chemotherapy.

Our immune system’s successful detection and destruction of abnormal cells is the hallmark of our body’s ability to either stop a malignancy from occurring or halt it once it has begun.

Daniela Delbeau, RN, clinical research nurse coordinator at the Perlmutter Cancer Center at NYU Langone Medical Center, discusses how individuals react differently to treatment.

Claire Friedman, MD, Memorial Sloan Kettering Cancer Center, discusses the promise of immunotherapy for elderly patients with melanoma.

Meredith Buxton, PhD, University of California San Francisco, discusses the I-SPY 2 trial, for which she is the executive director.

Michael A. Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses nurses’ roles in treating patients receiving immunotherapy, especially combination checkpoint blockades, which are typically associated with higher risks of adverse events.